Role for interferon-gamma release assays in latent tuberculosis screening before TNF-α antagonist therapy

Joint Bone Spine

Volumn 78, Issue 4, 2011, Pages 352-357

  Lioté, Huguette ^a   Lioté, Frédéric ^b,c,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b CENTRE VIGGO PETERSEN   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

Interferon gamma release assays; Skin test; TNF antagonists; Tuberculosis

Indexed keywords

ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAMNESIS; ASSAY; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE SURVEILLANCE; DRUG CONTRAINDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAPULMONARY TUBERCULOSIS; FOLLOW UP; GAMMA INTERFERON RELEASE ASSAY; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; INCIDENCE; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MILIARY TUBERCULOSIS; MONONUCLEAR CELL; PRIMARY TUBERCULOSIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; T LYMPHOCYTE; TUBERCULIN TEST; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL ASSAY; COMORBIDITY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC TESTS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MASS SCREENING; RISK FACTORS; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960634604     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.12.001     Document Type: Short Survey

References (51)

1. Keane J., Gershon S., Wise R.P. Tuberculosis associated with infliximab, a tumor necrosis factor neutralizing agent. N Engl J Med 2001, 345:1098-1104.
2. Gardam M.A., Keystone E.C. Anti-TNF agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 2003, 3:148-155.
3. Ehlers S. Why does TNF-targeted therapy reactivate tuberculosis?. J Rheumatol 2005, 32:35-39.
4. Hanekom W., Abel B., Scriba T. Immunological protection against tuberculosis. S Afr Med J 2007, 97:973-977.
5. Lioté H. Tuberculosis, anti-TNF agents and other immunosuppressants: evolution of preventitive strategies. Rev Mal Resp 2008, 25:1237-1249. [Article in French].
6. Wolfe F., Michaud K., Anderson J. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004, 50:372-379.
7. Gomez-Reino J.J., Carmona L., Valverde V.R., et al. BIOBADASER Group: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
8. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766-1772.
9. Askling J., Fored C.M., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52:1986-1992.
10. Seong S.S., Choi C.B., Woo J.H., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007, 34:706-711.
11. Wallis R.S. Reactivation of latent tuberculosis by TNF blockade: the role of interferon γ. J Investig Dermatol Symp Proc 2007, 12:16-21.
12. Tubach F., Salmon D., Ravaud P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor antibody therapy than with soluble tumor necrosis factor receptor therapy. Arthritis Rheum 2009, 60:1884-1894.
13. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528.
14. Harris J., Master S., De Haro S., et al. Th1-Th2 polarization and autophagy in the control of intracellular mycobacteria by macrophages. Vet Immunol Immunopathol 2009, 128:37-43.
15. Furst D.E., Cush J., Kaufmann F., et al. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002, 61:62-63.
16. Ledingham J., Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005, 44:157-163.
17. http://www.afssaps.sante.fr/.
18. Zabana Y., Domènech E., San Román A.L., et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008, 14:1387-1391.
19. Gomez-Reino J.J., Carmona L., Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
20. Hanta I., Ozbek S., Kuleci S., et al. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. Clin Rheumatol 2007, 26:1867-1870.
21. Bray M.G., Poulain C., Dougados M., et al. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment. Joint Bone Spine 2010, 77:135-141.
22. Vanhoof J., Landewe S., Van Wijngaerden E., et al. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003, 62:1241-1242.
23. Mor A., Bingham C.O., Kishimoto M., et al. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic. Ann Rheum Dis 2008, 67:462-465.
24. Larrey D. TNF a-antagonist hepatotoxicity. Joint Bone Spine 2008, 75:1208-1210.
25. Theis V., Rhodes J. Review article: minimizing tuberculosis during anti-TNF-a treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008, 27:19-30.
26. Tostmann A., Boeree M.J., Aarnoutse R.E., et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008, 23:192-202.
27. Sichletidis L., Settas L., Spyratos D., et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006, 10:1127-1132.
28. Raval A., Akhavan-Toyserkani G., Brinker A., et al. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007, 147:699-702.
29. Hermann J.L., Simonney N., Lagrange P.H. Advantages and drawbacks of in vitro interferon-γ/T cell assays compared to the Mantoux test for the diagnosis of tuberculosis. Rev Fr All Immunol Clin 2006, 46:543-547. [Article in French].
30. Diel R., Loddenkemper R., Nienhaus A. Evidence based comparison of commercial interferon-gamma release assays for detecting active tuberculosis - a meta-analysis. Chest 2010, 137:952-968.
31. Mack U., Migliori G.B., Sester M., et al. TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009, 33:956-973.
32. Bocchino M., Matarese A., Bellofiore B., et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008, 27:907-913.
33. Ponce de Leon D., Acevedo-Vasquez E., Alvizuri S., et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008, 35:776-781.
34. Vassilopoulos D., Stamoulis N., Hadziyannis E., et al. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008, 35:1271-1276.
35. Matulis G., Jüni P., Villiger P.M., et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008, 67:84-90.
36. Cobanoglu N., Ozcelik U., Kalyoncu U., et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007, 11:1177-1182.
37. Pratt A., Nicholl K., Kay L. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience. Rheumatology (Oxford) 2007, 46:1035-1036.
38. Behar S.M., Shin D.S., Maier A., et al. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol 2009, 36:546-551.
39. Schoepfer A.M., Flogerzi B., Fallegger S., et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008, 103:2799-2806.
40. Ferrara G., Losi M., Roversi P., et al. New tools for a better diagnosis of latent tuberculosis infection. Recenti Prog Med 2006, 97:123-128. [in Italian].
41. Dinser R., Fousse M., Sester U., et al. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay. Rheumatology (Oxford) 2008, 47:212-218.
42. Greenberg J.D., Reddy S.M., Schloss S.G., et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008, 35:770-775.
43. Soborg B., Ruhwald M., Hetland M.L., et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 2009, 36:1876-1884.
44. Bartalesi F., Vicidomini S., Goletti D., et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009, 33:586-593.
45. Sellam J., Hamdi H., Roy C., et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007, 66:1610-1615.
46. Martin J., Walsh C., Gibbs A., et al. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010, 69:181-185.
47. Ruhwald M., Bjerregaard-Andersen M., Rabna P., et al. CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes Infect 2007, 9:806-812.
48. Laffitte E., Janssens J.P., Roux-Lombard P., et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs tuberculin skin test. Br J Dermatol 2009, 161:797-800.
49. Pai M., Minion J., Sohn H., et al. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 2009, 30:701-716.
50. Lalvani A., Millington K.A. T-cell interferon-gamma release assays: can we do better?. Eur Respir J 2008, 32:1428-1430.
51. Ruhwald M., Petersen J., Kofoed K., et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS One 2008, 3:e2858.